|
WO2021063347A1
|
|
Compound and preparation method therefor and use thereof
|
|
WO2021027792A1
|
|
Vmat2 inhibitor and preparation method therefor and application thereof
|
|
CN111437284A
|
|
Sodium aescinate pharmaceutical composition and preparation method thereof
|
|
CN110548016A
|
|
anti-Epha3 antibody modified nanoparticles transnasally administered to brain and uses thereof
|
|
WO2019149159A1
|
|
Composition comprising oxadiazole derivative, preparation method therefor and use thereof
|
|
EP3700531A1
|
|
Dosage regimen of paliperidone palmitate extended-release injectable suspension
|
|
WO2019047920A1
|
|
Crystal form of oxadiazole derivative as ido1 inhibitor and preparation method therefor
|
|
WO2018228381A1
|
|
Method for preparing 1,2,5-oxadiazole compound, and intermediate thereof
|
|
WO2018214958A1
|
|
Crystal form of ido1 inhibitor and preparation method therefor
|
|
CN109954145A
|
|
A kind of Exenatide oral administration nanometer particle
|
|
CN109954146A
|
|
A kind of Exenatide oral administration nanometer particle
|
|
CN109776539A
|
|
Entecavir long-chain ester and its preparation method and application
|
|
CN108218725A
|
|
A kind of preparation method of O-DMV
|
|
CN108057030A
|
|
A kind of nose administration rotigotine nanoparticle
|
|
CA3030043A1
|
|
Rotigotine behenate, preparation method and use thereof
|
|
CN105663279A
|
|
Preparation method of total saponins of rhizoma cimicifugae
|
|
CN105372339A
|
|
Method for rapidly detecting trace amount of rotigotine
|
|
EP2987484A1
|
|
Goserelin sustained release microsphere pharmaceutical composition
|
|
TW201429964A
|
|
5,6,7,8-tetrahydro-6-[n,n-bis[(2-thienyl)ethyl]]amino-1-naphthol, and preparing method and use thereof
|
|
TW201514172A
|
|
5,6,7,8-tetrahydro-6-[n,n-bis[(2-thienyl)ethyl]]amino-1-naphthol, and preparing method and use thereof
|
